Home » News » Urology » Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
LATEST BENIGN PROSTATIC HYPERPLASIA (BPH) NEWS
5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).
In less than 3 months after procedure, only mild urinary symptoms reported; benefits persisted through 6 years
Average video score was 6.65; only 24.3% of videos emphasized critical steps of surgery
This Swedish population-based study has the largest sample size to date exploring these associations.
Association especially strong among the elderly male population
TG/HDL-C and TC/HDL-C ratios associated with BPH; TG/HDL-C may be risk factor for BPH with normal TG, HDL-C
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
But rate of retrograde ejaculation higher following many surgical procedures for benign prostatic hyperplasia
Investigators in South Korea demonstrated the benefit in a retrospective study that included 651 men undergoing transurethral resection of the prostate.
Rates of reinterventions low for persistence or regrowth of prostate adenoma, long-term complications.
Load More
Open
Next post in Benign Prostatic Hyperplasia (BPH)
Close
Close more info about Prostate Artery Embolization Effective Long Term for Prostate-Related Urinary Symptoms
Loading...
Close more info about Prostate Artery Embolization Effective Long Term for Prostate-Related Urinary Symptoms
Loading...